Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients

ConclusionsThis retrospective study suggests that, after a median follow-up of 3  months under enzalutamide or abiraterone, PSMA expression changes on PET/CT are strongly associated with response to treatment. Prospective studies are needed to better understand PSMA expression dynamics following the start of enzalutamide and abiraterone, along with the role of PSMA PET/CT in re sponse assessment.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research